Given that MTAP deletion occursin approximately 10–15% of all human cancer, and that thereare at least 15 cancer types where the frequency of MTAP loss occurs in ≥10% of patients,7,12 moleculesthat selectively kill MTAP-null cancer cells provide a striking opportunityto deliver a targeted treatment to a significant patient population. This evidence concerns the gene MTAP and cancer.